Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment

Archives of General Psychiatry

Volumn 54, Issue 5, 1997, Pages 453-463

  Schooler, Nina R ^a   Keith, Samuel J ^h   Severe, Joanne B ^h   Matthews, Susan M ^h   Bellack, Alan S ^c   Glick, Ira D ^d   Hargreaves, William A ^e,f   Kane, John M ^b   Ninan, Philip T ^g   Frances, Allen ^d   Jacobs, Marc ^e,f   Lieberman, Jeffrey A ^b   Mance, Rosalind ^g   Simpson, George M ^c   Woerner, Margaret G ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Medical College of Pennsylvania   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g EMORY UNIVERSITY   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE;

ADULT; ARTICLE; DOSE RESPONSE; FAMILY THERAPY; FEMALE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RANDOMIZATION; RELAPSE; SCHIZOPHRENIA; SOCIAL SUPPORT;

EID: 0030914609     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830170079011     Document Type: Article

References (58)

1. Kane J, Schooler NR, Marder SR, Simpson GM, Casey DE. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:345-372.
2. Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry. 1975;132:1237-1245.
3. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull. 1991;17:311-324.
4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19:287-302.
5. Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry. 1978; 35:1169-1177
6. Kane JM, Ritkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry. 1983;40:893-896.
7. Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, Borenstein M. High dose vs low dose strategies in the treatment of schizophrenia. Psychopharmacol Bull. 1985;21:533-537.
8. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low dose regimens. J Clin Psychiatry. 1986;47 (suppl):30-33.
9. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PRA. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry. 1984; 41:1025-1029.
10. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low and conventional dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry. 1987;44:518-521.
11. Johnson DAW, Ludlow JM, Street K, Taylor RDW. Double-Wind comparison of half-dose and standard flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. Br J Psychiatry. 1987;151:634-638.
12. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RJ, Carter M, Madonia JM, Environmental/Personal Indicators in the Course of Schizophrenia Research Group. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry. 1988; 45:797-805.
13. Kane JM, Davis JM, Schooler NR, Marder SR, Brauzer B, Casey DE. A one-year comparison of four dosages of haloperidol decanoate. Schizophr Res. 1993;9:239-240.
14. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry. 1982;139:918-922.
15. Herz MI, Glazer WM, Mostert MA, Sheard MH, Szymanski HV, Hafez H, Mirza M, Vaha J. Intermittent vs maintenance medication in schizophrenia. Arch Gen Psychiatry. 1991;48:333-339.
16. Carpenter WT Jr, Hanlon TE, Heinrichs DW, Kirkpatrick B, Levine J, Buchanan RW. Continuous vs targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147:1138-1148.
17. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298:985-990.
18. Jolley AG, Hirsch SR, Morrison E, McRink A. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301:837-842.
19. Pietzcker A, Gaebel W, Kopcke W. A German multi-center study on the neuroleptic long-term therapy of schizophrenic patients: preliminary report. Pharmacopsychiatry. 1986;19:161-166.
20. Pietzcker A, Gaebel W, Kopcke W, Linden M, Müller P, Müller-Spahn S, Tiegler J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2 year results of a German multicenter study. J Psychiatr Res. 1993; 27:321-339.
21. Keith SJ, Schooler NR. Psychosocial and psychotherapeutic strategies for long-term treatment of schizophrenia. In: Costa e Silva JA, Nadelson CC, eds. International Review of Psychiatry. Washington, DC: American Psychiatric Press Inc; 1993:229-262.
22. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophr Res. 1993;19:317-336.
23. Schooler NR, Keith SJ, Severe JB, Matthews SM. Maintenance treatment of schizophrenia: a review of dose reduction and family management strategies. Psychiatr Q. 1995;66:279-292.
24. Falloon IRH, Boyd JL, McGill CW, Razani J, Moss HB, Gilderman AM. Family management in the prevention of exacerbations of schizophrenia. N Engl J Med. 1982;306:1437-1440.
25. Falloon IRH, Boyd J, McGill C, Williamson M, Razani J, Moss HG, Gilderman AM, Simpson GM. Family management in the prevention of morbidity of schizophrenia: clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry. 1985;42:887-896.
26. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, I: one-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry. 1986;43:633-642.
27. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RJ, Carter M, the Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, II: two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry. 1991;48:340-347.
28. Leff J, Kuipers L, Berkowitz R, Ebertein-Vries R, Sturgeon D. A controlled trial of social intervention in the families of schizophrenic patients. Br J Psychiatry. 1982;141:121-134.
29. Leff J, Kuipers L, Berkowitz R, Sturgeon D. A controlled trial of social intervention in the families of schizophrenic patients: two year follow-up. Br J Psychiatry. 1985;146:594-600.
30. Randolph ET, Eth S, Glynn S, Paz GB, Leong GB, Shaner AL, Strachan A, Van Vort W, Escobar J, Liberman RP. Behavioural family management in schizophrenia, outcome from a clinic-based intervention. Br J Psychiatry. 1994;144: 501-506.
31. Leff JP, Berkowitz R, Shavit N, Strachan A, Glass I, Vaughn C. A trial of family therapy versus a relatives' group for schizophrenia. Br J Psychiatry. 1989;154:58-66.
32. Leff J, Berkowitz R, Shavit N, Strachan A, Glass I, Vaughn C. A trial of family therapy versus a relatives' group for schizophrenia: two-year follow-up. Br J Psychiatry. 1990;157:571-577.
33. McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Dunne EJ, Horen B, Newmark M, Toran J. The multiple family group, psychoeducation, and maintenance medication in the treatment of schizophrenia. Arch Gen Psychiatry. 1995;52:679-687.
34. Tarrier N, Barrowclough C, Vaughn C, Bamrah JS, Porceddu K, Watts D, Freeman H. The community management of schizophrenia: a controlled trial of a behavioural intervention with families to reduce relapse. Br J Psychiatry. 1988; 153:532-542.
35. Tarrier N, Barrowclough C, Vaughn C, Bamrah JS, Porceddu K, Watts D, Freeman H. Community management of schizophrenia: a two-year follow-up of a behavioural intervention with families. Br J Psychiatry. 1989;154:625-628.
36. Zastowny TR, Lehman AF, Cole RE, Kane C. Family management of schizophrenia: a comparison of behavioral and supportive family treatment. Psychiatr Q. 1992;63:159-186.
37. Falloon IRH, Boyd JL, McGill CW. Family Care for Schizophrenia: A Problem-Solving Approach to Mental Illness. New York, NY: Guilford Press; 1984.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
39. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep. 1962;10:799-812.
40. Woerner MG, Mannuza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24:112-117.
41. Anderson CM, Reiss DJ, Hogarty G. Schizophrenia in the Family. New York, NY: Guilford Press; 1986.
42. Falloon IRH, McGill CW, Matthews SM, Keith SJ, Schooler NR. Family treatment for schizophrenia: the design and research application of therapist training models. J Psychother Prac Res. 1996;5:45-56.
43. Falloon I, Mueser K, Gingerich S, Rappaport S, McGill C, Hole V. Behavioural Family Therapy: A Workbook. Buckingham, England: Buckingham Mental Health Services; 1988.
44. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.
45. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer. 1978;37:849-857.
46. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1983.
47. Mueser KT, Sayers SL, Schooler NR, Mance R, Haas GL. A multi-site investigation of the reliability of the Scale for the Assessment of Negative Symptoms. Am J Psychiatry. 1994;151:1453-1462.
48. Guy W. EDCEU Assessment Manual for Psychopharmacology. Rockville, Md: Dept of Health, Education and Welfare, National Institute of Mental Health; 1976. Publication (ADM)76-338.
49. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand. 1970;212(suppl):17-19.
50. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980;137:801-805.
51. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
52. Keith SJ, Bellack A, Frances A, Mance R, Matthews S, the Treatment Strategies in Schizophrenia Collaborative Study Group. The influence of diagnosis and family treatment on acute treatment response and short term outcome in schizophrenia. Psychopharmacol Bull. 1989;25:336-339.
53. Robinson D, Woerner M, Pollack S, Lerner G. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol. 1996;16:170-176.
54. Schooler NR, Keith SJ, Severe JB, Matthews S, the Treatment Strategies in Schizophrenia Collaborative Study Group. Acute treatment response and short term outcome in schizophrenia: first results of the NIMH Treatment Strategies in Schizophrenia Study. Psychopharmacol Bull. 1989;25:331-335.
55. Hargreaves WA, Kane JM, Ninan PT, Severe JB, Woerner M, the Treatment Strategies in Schizophrenia Collaborative Study Group. Demographic characteristics, treatment history, presenting psychopathology and early course in schizophrenia. Psychopharmacol Bull. 1989;25:340-343.
56. Glick ID, Jacobs M, Lieberman J, Simpson G, Schooler NR, the Treatment Strategies in Schizophrenia Collaborative Study Group. Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Psychopharmacol Bull. 1989;25:344-347.
57. Kane JM, Risperidone. Am J Psychiatry. 1994;151:802-803.
58. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.